相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of lenvatinib in the real-world treatment of hepatocellular carcinoma: Results from a Canadian multicenter database (HCC CHORD).
Carla Pires Amaro et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma
Soojin Kim et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)
Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea
Myung Ji Goh et al.
LIVER CANCER (2021)
Expert Consensus on the Management of Adverse Events During Treatment with Lenvatinib for Thyroid Cancer
N. Reed et al.
CLINICAL ONCOLOGY (2020)
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Real-world experience with Lenvatinib in the management of Hepatocellular Carcinoma: A single-center Indian experience.
Amit Rauthan et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Team-Based Approach to Management of Hypertension Associated with Angiogenesis Inhibitors
Shreya Patel et al.
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis
Jaekyung Cheon et al.
LIVER CANCER (2020)
Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study
Shigeo Shimose et al.
CANCERS (2020)
Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China
Dong-Xu Wang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2020)
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial
Thomas Yau et al.
JAMA ONCOLOGY (2020)
Impact of Adverse Events on the Progression-Free Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study
Takamasa Ohki et al.
DRUGS-REAL WORLD OUTCOMES (2020)
Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting
Takuya Sho et al.
JGH OPEN (2020)
Vascular Cardio-Oncology: Vascular Endothelial Growth Factor inhibitors and hypertension
Jorie Versmissen et al.
CARDIOVASCULAR RESEARCH (2019)
Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT).
Max W. Sung et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Urine protein: creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma
Thomas R. Jeffry Evans et al.
BRITISH JOURNAL OF CANCER (2019)
Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib
R. Mauceri et al.
INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2019)
Hypertension in Cancer Patients and Survivors Epidemiology, Diagnosis, and Management
Jordana B. Cohen et al.
JACC: CARDIOONCOLOGY (2019)
Expert opinion on thyroid complications of new anti-cancer therapies: Tyrosine kinase inhibitors
Delphine Drui et al.
ANNALES D ENDOCRINOLOGIE (2018)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Tyrosine Kinase Inhibitor-Induced Hypertension
Megha Agarwal et al.
CURRENT ONCOLOGY REPORTS (2018)
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A. Vogel et al.
ANNALS OF ONCOLOGY (2018)
Optimal management of patients with hepatocellular carcinoma treated with lenvatinib
Masafumi Ikeda et al.
EXPERT OPINION ON DRUG SAFETY (2018)
Exercise and other non-pharmaceutical interventions for cancer-related fatigue in patients during or after cancer treatment: a systematic review incorporating an indirect-comparisons meta-analysis
Roger Hilfiker et al.
BRITISH JOURNAL OF SPORTS MEDICINE (2018)
Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
Kenji Ikeda et al.
JOURNAL OF GASTROENTEROLOGY (2017)
Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses
Toshiyuki Tamai et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue A Meta-analysis
Karen M. Mustian et al.
JAMA ONCOLOGY (2017)
Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
Masafumi Ikeda et al.
CLINICAL CANCER RESEARCH (2016)
Should we use the angiotensin-converting enzyme inhibitors for the treatment of anti-VEGF-induced hypertension?
G. Emile et al.
ANNALS OF ONCOLOGY (2014)
Treatment of Hypertension and Renal Injury Induced by the Angiogenesis Inhibitor Sunitinib Preclinical Study
Stephanie Lankhorst et al.
HYPERTENSION (2014)
Dysphonia induced by anti-angiogenic compounds
Erika Saavedra et al.
INVESTIGATIONAL NEW DRUGS (2014)
Proteinuria and hypertension with tyrosine kinase inhibitors
Praveen Kandula et al.
KIDNEY INTERNATIONAL (2011)
Efficacy of Diosmectite (Smecta)® in the Treatment of Acute Watery Diarrhoea in Adults: A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study
Faouzi Khediri et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2011)
Dysphonia induced by vascular endothelium growth factor/vascular endothelium growth factor receptor inhibitors
Dana M. Hartl et al.
INVESTIGATIONAL NEW DRUGS (2010)
Relation Between Kidney Function, Proteinuria, and Adverse Outcomes
Brenda R. Hemmelgarn et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors
Michael L. Maitland et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis
Kunihiro Matsushita et al.
LANCET (2010)
Hoarseness during treatment with bevacizumab and other vascular endothelial growth factor signalling inhibitors
Hilda Wong et al.
ACTA ONCOLOGICA (2009)
Search for Evidence-Based Approaches for the Prevention and Palliation of Hand-Foot Skin Reaction (HFSR) Caused by the Multikinase Inhibitors (MKIs)
Roger Anderson et al.
ONCOLOGIST (2009)
Evolving Strategies for the Management of Hand-Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib
Mario E. Lacouture et al.
ONCOLOGIST (2008)
Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor/fetal liver kinase-1/NO pathway
Shin-ichiro Miura et al.
HYPERTENSION RESEARCH (2005)
分享论文
